Cargando…
Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study
OBJECTIVE: To evaluate the effects of metformin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients with diabetes using the Taiwanese National Health Insurance Research Database. RESEARCH DESIGN AND METHODS: In total, 7,620 patients were eligible in this study, among them,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766148/ https://www.ncbi.nlm.nih.gov/pubmed/29329345 http://dx.doi.org/10.1371/journal.pone.0191129 |
_version_ | 1783292324028088320 |
---|---|
author | Chuang, Min-Chun Yang, Yao-Hsu Tsai, Ying-Huang Hsieh, Meng-Jer Lin, Yu-Ching Lin, Chin-Kuo Chen, Pau-Chung Yang, Tsung-Ming |
author_facet | Chuang, Min-Chun Yang, Yao-Hsu Tsai, Ying-Huang Hsieh, Meng-Jer Lin, Yu-Ching Lin, Chin-Kuo Chen, Pau-Chung Yang, Tsung-Ming |
author_sort | Chuang, Min-Chun |
collection | PubMed |
description | OBJECTIVE: To evaluate the effects of metformin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients with diabetes using the Taiwanese National Health Insurance Research Database. RESEARCH DESIGN AND METHODS: In total, 7,620 patients were eligible in this study, among them, 3,578 patients were metformin users and 4,042 were non-users. Propensity score matching was used to reduce possible confounding factors. In total, 4,182 patients (2,091 matched pairs) were included in the matched cohort. Cox proportional hazard model with time-dependent covariate were also applied to evaluate the association between metformin use and overall survival (OS). RESULTS: A total of 3,578 patients were metformin users at the time of diagnosis of NSCLC. Cox proportional hazard model with time-dependent covariate revealed that metformin use was associated with a significantly longer OS (HR: 0.85, 95.0% CI: 0.80–0.90). The survival benefit of metformin use was maintained after propensity score matching at a ratio of 1:1 (HR: 0.90, 95.0% CI: 0.84–0.97). CONCLUSIONS: Metformin use is associated with longer OS in inoperable NSCLC patients with diabetes, suggesting a potential anti-tumorigenic effect for metformin. Further research is needed to investigate the actual role of metformin in the treatment of NSCLC patients with diabetes. |
format | Online Article Text |
id | pubmed-5766148 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57661482018-01-23 Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study Chuang, Min-Chun Yang, Yao-Hsu Tsai, Ying-Huang Hsieh, Meng-Jer Lin, Yu-Ching Lin, Chin-Kuo Chen, Pau-Chung Yang, Tsung-Ming PLoS One Research Article OBJECTIVE: To evaluate the effects of metformin use on the survival of inoperable non-small cell lung cancer (NSCLC) patients with diabetes using the Taiwanese National Health Insurance Research Database. RESEARCH DESIGN AND METHODS: In total, 7,620 patients were eligible in this study, among them, 3,578 patients were metformin users and 4,042 were non-users. Propensity score matching was used to reduce possible confounding factors. In total, 4,182 patients (2,091 matched pairs) were included in the matched cohort. Cox proportional hazard model with time-dependent covariate were also applied to evaluate the association between metformin use and overall survival (OS). RESULTS: A total of 3,578 patients were metformin users at the time of diagnosis of NSCLC. Cox proportional hazard model with time-dependent covariate revealed that metformin use was associated with a significantly longer OS (HR: 0.85, 95.0% CI: 0.80–0.90). The survival benefit of metformin use was maintained after propensity score matching at a ratio of 1:1 (HR: 0.90, 95.0% CI: 0.84–0.97). CONCLUSIONS: Metformin use is associated with longer OS in inoperable NSCLC patients with diabetes, suggesting a potential anti-tumorigenic effect for metformin. Further research is needed to investigate the actual role of metformin in the treatment of NSCLC patients with diabetes. Public Library of Science 2018-01-12 /pmc/articles/PMC5766148/ /pubmed/29329345 http://dx.doi.org/10.1371/journal.pone.0191129 Text en © 2018 Chuang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Chuang, Min-Chun Yang, Yao-Hsu Tsai, Ying-Huang Hsieh, Meng-Jer Lin, Yu-Ching Lin, Chin-Kuo Chen, Pau-Chung Yang, Tsung-Ming Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
title | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
title_full | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
title_fullStr | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
title_full_unstemmed | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
title_short | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
title_sort | survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: a population-based retrospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766148/ https://www.ncbi.nlm.nih.gov/pubmed/29329345 http://dx.doi.org/10.1371/journal.pone.0191129 |
work_keys_str_mv | AT chuangminchun survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy AT yangyaohsu survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy AT tsaiyinghuang survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy AT hsiehmengjer survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy AT linyuching survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy AT linchinkuo survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy AT chenpauchung survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy AT yangtsungming survivalbenefitassociatedwithmetforminuseininoperablenonsmallcelllungcancerpatientswithdiabetesapopulationbasedretrospectivecohortstudy |